Volume 7.29 | Jul 30

Mammary Cell News 7.29 July 30, 2015
Mammary Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   MCN on Twitter
 
TOP STORY
SLC9A3R1 Stimulates Autophagy via BECN1 Stabilization in Breast Cancer Cells
Scientists report that the stability of BECN1, the major component of the autophagic core lipid kinase complex, is augmented in SLC9A3R1 (solute carrier family 9, subfamily A, member 3 regulator 1)-overexpressing breast cancer MDA-MB-231 cells, subsequently stimulating autophagy by attenuating the interaction between BECN1 and BCL2. [Autophagy] Abstract
Dissociation Enzymes For Optimized Human Mammary Tissue Dissociation and Culture FREE Protocols
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

DOT1L Cooperates with the c-Myc-p300 Complex to Epigenetically Derepress CDH1 Transcription Factors in Breast Cancer Progression
Scientists identified that DOT1L cooperates with c-Myc and p300 acetyltransferase to epigenetically activate epithelial–mesenchymal transition regulators in breast cancer progression. [Nat Commun] Full Article

Disrupting Na+,HCO3-Cotransporter NBCn1 (Slc4a7) Delays Murine Breast Cancer Development
Genome-wide association studies have indicated a possible link between the Na+,HCO3-cotransporter NBCn1 and breast cancer. Researchers tested the functional consequences of NBCn1 knockout for breast cancer development. [Oncogene] Abstract

Deacetylation of HSPA5 by HDAC6 Leads to GP78-Mediated HSPA5 Ubiquitination at K447 and Suppresses Metastasis of Breast Cancer
Researchers identified that the specific lysine residue 447 (K447) of heat-shock protein 5 (HSPA5) could be modified with polyubiquitin for subsequent degradation through the ubiquitin proteasomal system, leading to the suppression of cell migration and invasion of breast cancer. [Oncogene] Abstract

PKCζ Promotes Breast Cancer Invasion by Regulating Expression of E-Cadherin and Zonula Occludens-1 (ZO-1) via NFκB-p65
Investigators report a possible mechanism of oncogenic protein kinase C zeta (PKCζ) signaling in the context of breast cancer. They observed that depletion of PKCζ promotes epithelial morphology in mesenchymal-like MDA-MB-231 cells. [Sci Rep] Full Article

Anti-Angiogenesis Therapy and Gap Junction Inhibition Reduce MDA-MB-231 Breast Cancer Cell Invasion and Metastasis In Vitro and In Vivo
Scientists evaluated avastin, an anti-VEGF antibody; and oleamide, a gap junction inhibitor, using MDA-MB-231 human breast cancer cells in vitro and a xenograft murine model in vivo. [Sci Rep] Full Article

Identification of Estrogen Response Element in Aquaporin-3 Gene that Mediates Estrogen-Induced Cell Migration and Invasion in Estrogen Receptor-Positive Breast Cancer
The authors investigated whether aquaporin-3 (AQP3), one of the aquaporins expressed highly in breast cancer, had any clinical implication in estrogen-receptor positive breast cancer, and explored the regulatory mechanisms of AQP3 in estrogen-related breast cancer progression. [Sci Rep] Full Article

Epiregulin Contributes to Breast Tumorigenesis through Regulating Matrix Metalloproteinase 1 and Promoting Cell Survival
Gene knock-down approaches using shRNA-based strategies were used to determine the requirement of epidermal growth factor family member epiregulin (EREG) for growth of MCF10DCIS cells in vivo, and for identifying mechanisms through which EREG promotes tumor cell survival. [Mol Cancer] Full Article

Interactions between αv-Integrin and HER2 and Their Role in the Invasive Phenotype of Breast Cancer Cells In Vitro and in Rat Brain
Clones of MDA-MB231BR human breast cancer cells with stable knock down of αv-integrin in combination with high or low levels of HER2 were created. The interactions of these two proteins and their combined effect on cell migration and invasion were investigated in vitro and in vivo. [PLoS One] Full Article

CLINICAL RESEARCH

Aromatase Inhibitors versus Tamoxifen in Early Breast Cancer: Patient-Level Meta-Analysis of the Randomized Trials
The authors undertook meta-analyses of individual data on 31,920 postmenopausal women with estrogen-receptor-positive early breast cancer in the randomized trials of five years of aromatase inhibitor versus five years of tamoxifen; of five years of aromatase inhibitor versus two to three years of tamoxifen then aromatase inhibitor to year five; and of two to three years of tamoxifen then aromatase inhibitor to year five versus five years of tamoxifen. [Lancet] Full Article

Long-Term Safety and Anti-Tumor Activity of Olaparib Monotherapy after Combination with Carboplatin and Paclitaxel in Patients with Advanced Breast, Ovarian or Fallopian Tube Cancer
Patients had first participated in a Phase I study of olaparib combined with carboplatin and/or paclitaxel. They continued with olaparib monotherapy in their best interest if they failed to tolerate the combination due to the treatment-related adverse events. [Br J Cancer] Abstract

Cryopreservation Media for Stem Cells - Learn More!
 
REVIEWS
Epithelial-Mesenchymal Transition and Drug Resistance in Breast Cancer
Recently, mounting evidence has demonstrated involvement of epithelial-mesenchymal transition (EMT) in antagonizing chemotherapy in breast cancer. The authors discuss the biological significance and clinical implications of these findings, with an emphasis on novel approaches that effectively target EMT to increase the efficacy of anticancer therapies. [Cytokine Growth Factor Rev] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
 
SCIENCE NEWS
Advaxis’s Scientific Founder to Present on ADXS-HER2
Advaxis, Inc. announced that the company’s scientific founder, Yvonne Paterson, PhD will give a presentation titled “HER-2/neu as a target for Listeria-based cancer immunotherapy for breast cancer.” [Press release from Advaxis, Inc. discussing research to be presented at the 2015 World Congress on Breast Cancer, Birmingham] Press Release

From our sponsor: Want to learn more about the intestinal epithelium? Request a free wallchart from Cell.
 
INDUSTRY NEWS
CDRD & OICR Team up to Advance Cutting-Edge New Cancer Treatments
Two of Canada’s leading drug research and commercialization centers have announced a call for proposals to help bring new cancer treatments to patients through collaborative technology-development projects from academic investigators across Canada. [Center for Drug Research and Development (CDRD)] Press Release

Baylor’s Dan L. Duncan Cancer Center Receives Highest National Cancer Institute Designation–Comprehensive Status
The National Cancer Institute has awarded the Dan L. Duncan Cancer Center at Baylor College of Medicine the prestigious designation of a Comprehensive Cancer Center. The Comprehensive Cancer Center designation includes a $14.5 million, five-year grant. [Baylor College of Medicine] Press Release

University of Toronto to Transform Regenerative Medicine Thanks to Historic $114 Million Federal Grant
The University of Toronto is set to cement its position as one of the world’s leading centers for the design and manufacture of cells, tissues and organs that can be used to treat degenerative disease, thanks to a $114-million grant from the federal government. [University of Toronto] Press Release
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW ISOBM 2015 Oncology in the Biomarker Era: Biology – Diagnostics – Therapy
October 3-7, 2015
Zakopane, Poland

Visit our events page to see a complete list of events in the mammary cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Position – Cancer Biology (Northwestern University)

NEW Postdoctoral Position – Inflammation & Breast Tumor Metastasis (Stephenson Cancer Center)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Cancer Research (National University of Singapore)

Senior Product Manager – Breast Cancer (Celgene Corporation)

Postdoctoral Research Fellow (Fred Hutchinson Cancer Research Center)

Research Associate/Assistant Professor – Breast Cancer (University of Chicago)

Postdoctoral Research Associate – Breast Stem Cell Biology (University of Miami Miller School of Medicine)

Postdoctoral Fellow – Oncolytic Viruses (Mayo Clinic – Rochester)

Postdoctoral Positions – Breast Cancer (University of Texas MD Anderson Cancer Center)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us